Business
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectivity and reduced off-target activity compared to CDK2 inhibitors Oral presentation on April 21, 2026, at 2:30 p.m. PT BOSTON, April 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based med
About this update from Monte Rosa Therapeutics, Inc.
[{"type":"image","alt":"Monte Rosa Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Monte Rosa Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/c99f028be58427489eba79299e175651"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fIhey1p_FM7t0hRxxCU_wA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNQ--/https://media.zenfs.com/en/globenewswire.com/c99f028be58427489eba79299e175651","width":300,"height":82}},"lazy":false},{"type":"text","content":"CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers ","length":149,"tagName":"p"},{"type":"text","content":"CCNE1-directed MGD demonstrated superior selectivity and reduced off-target activity compared to CDK2 inhibitors ","length":112,"tagName":"p"},{"type":"text","content":"Oral presentation on April 21, 2026, at 2:30 p.m. PT","length":52,"tagName":"p"},{"type":"text","content":"BOSTON, April 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data highlighting the potential of its highly selective, first-in-class cyclin E1 (CCNE1)-directed MGD, MRT-55811, to treat CCNE1-amplified solid tumors at the American Association for Cancer Research (AACR) Annual Meeting 2026, being held April 17-22 in San Diego, CA.","length":519,"tagName":"p"},{"type":"text","content":"“CCNE1 MGDs represent a first-in-class opportunity to directly target a frequently amplified driver oncogene in several solid tumor cancer populations with high unmet medical need. In CCNE1-amplified in vivo models of ovarian, gastric, and breast cancer, MRT-55811 demonstrated compelling monotherapy anti-tumor activity,” said Sharon Townson, Ph.D., Chief Scientific Officer of Monte Rosa Therapeutics. “MRT-55811 also exhibited superior selectivity when compared to clinical-stage CDK2 inhibitors, suggesting that our CCNE1-directed MGDs could avoid the dose-limiting toxicities reported for these less selective agents. We believe that our oral CCNE1 degrader has the potential to provide clinical benefit across multiple cancer types where CCNE1 is amplified. Thes...